Showing results (11-20 of 34) with videos related to
Sort By:
Pageof 4
AIDS (London, England)|October 4, 2008
The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patientsJoel E Gallant, Jonathan A Winston, Edwin DeJesus, et al.The Journal of Infectious Diseases|March 20, 2004
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virusGregory J Dore, David A Cooper, Anton L Pozniak, et al.The Journal of Infectious Diseases|February 12, 2010
Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trialAndrew R Zolopa, Daniel S Berger, Harry Lampiris, et al.HIV Clinical Trials|November 29, 2007
The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapyJosé R Valdez Madruga, Isabel Cassetti, Jamal Muhamad A H Suleiman, et al.HIV Clinical Trials|October 29, 2014
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patientsRima Kulkarni, Michael E Abram, Damian J McColl, et al.AIDS (London, England)|June 5, 2002
Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind studyRobert T Schooley, Peter Ruane, Robert A Myers, et al.The Lancet. Infectious Diseases|October 22, 2011
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority studyJean-Michel Molina, Anthony Lamarca, Jaime Andrade-Villanueva, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|August 29, 2006
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patientsEdwin DeJesus, Daniel Berger, Martin Markowitz, et al.HIV Clinical Trials|October 23, 2013
Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimensAnthony M Mills, Calvin Cohen, Edwin Dejesus, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|December 4, 2014
Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairmentFrank A Post, Jonathan Winston, Jaime F Andrade-Villanueva, et al.Pageof 4